Immune Signature Linked to COVID-19 Severity : A SARS-Score for Personalized Medicine
Copyright © 2021 Russick, Foy, Josseaume, Meylan, Hamouda, Kirilovsky, Sissy, Tartour, Smadja, Karras, Hulot, Livrozet, Fayol, Arlet, Diehl, Dragon-Durey, Pagès and Cremer..
SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of hospitalized patients has become a worldwide concern and identification of immune biomarkers predictive of the clinical outcome for hospitalized patients remains a major challenge. Immunophenotyping and transcriptomic analysis of hospitalized COVID-19 patients at admission allow identifying the two categories of patients. Inflammation, high neutrophil activation, dysfunctional monocytic response and a strongly impaired adaptive immune response was observed in patients who will experience the more severe form of the disease. This observation was validated in an independent cohort of patients. Using in silico analysis on drug signature database, we identify differential therapeutics that specifically correspond to each group of patients. From this signature, we propose a score-the SARS-Score-composed of easily quantifiable biomarkers, to classify hospitalized patients upon arrival to adapt treatment according to their immune profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 12(2021) vom: 15., Seite 701273 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Russick, Jules [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 17.08.2021 Date Revised 07.11.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2021.701273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328667706 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328667706 | ||
| 003 | DE-627 | ||
| 005 | 20231226203348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2021.701273 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328667706 | ||
| 035 | |a (NLM)34322128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Russick, Jules |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune Signature Linked to COVID-19 Severity |b A SARS-Score for Personalized Medicine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Russick, Foy, Josseaume, Meylan, Hamouda, Kirilovsky, Sissy, Tartour, Smadja, Karras, Hulot, Livrozet, Fayol, Arlet, Diehl, Dragon-Durey, Pagès and Cremer. | ||
| 520 | |a SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of hospitalized patients has become a worldwide concern and identification of immune biomarkers predictive of the clinical outcome for hospitalized patients remains a major challenge. Immunophenotyping and transcriptomic analysis of hospitalized COVID-19 patients at admission allow identifying the two categories of patients. Inflammation, high neutrophil activation, dysfunctional monocytic response and a strongly impaired adaptive immune response was observed in patients who will experience the more severe form of the disease. This observation was validated in an independent cohort of patients. Using in silico analysis on drug signature database, we identify differential therapeutics that specifically correspond to each group of patients. From this signature, we propose a score-the SARS-Score-composed of easily quantifiable biomarkers, to classify hospitalized patients upon arrival to adapt treatment according to their immune profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a immunologic profile | |
| 650 | 4 | |a personalized medicine/personalized health care | |
| 650 | 4 | |a score | |
| 650 | 4 | |a therapeutic strategy | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Foy, Pierre-Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Josseaume, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Meylan, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Hamouda, Nadine Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Kirilovsky, Amos |e verfasserin |4 aut | |
| 700 | 1 | |a Sissy, Carine El |e verfasserin |4 aut | |
| 700 | 1 | |a Tartour, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Smadja, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Karras, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Hulot, Jean-Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Livrozet, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Fayol, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Arlet, Jean-Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Diehl, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Dragon-Durey, Marie-Agnès |e verfasserin |4 aut | |
| 700 | 1 | |a Pagès, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Cremer, Isabelle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 12(2021) vom: 15., Seite 701273 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:15 |g pages:701273 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2021.701273 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |b 15 |h 701273 | ||